- Home
- KTCC vs AKTX Comparison
KTCC vs AKTX Comparison
Compare KTCC & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTCC
- AKTX
- Stock Information
- Founded
- KTCC 1969
- AKTX N/A
- Country
- KTCC United States
- AKTX United States
- Employees
- KTCC N/A
- AKTX N/A
- Industry
- KTCC Electrical Products
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- KTCC Technology
- AKTX Health Care
- Exchange
- KTCC Nasdaq
- AKTX Nasdaq
- Market Cap
- KTCC 31.2M
- AKTX 35.7M
- IPO Year
- KTCC N/A
- AKTX N/A
- Fundamental
- Price
- KTCC $2.78
- AKTX $0.95
- Analyst Decision
- KTCC
- AKTX Strong Buy
- Analyst Count
- KTCC 0
- AKTX 1
- Target Price
- KTCC N/A
- AKTX $5.00
- AVG Volume (30 Days)
- KTCC 15.3K
- AKTX 35.2K
- Earning Date
- KTCC 08-27-2025
- AKTX 08-13-2025
- Dividend Yield
- KTCC N/A
- AKTX N/A
- EPS Growth
- KTCC N/A
- AKTX N/A
- EPS
- KTCC N/A
- AKTX N/A
- Revenue
- KTCC $483,941,000.00
- AKTX N/A
- Revenue This Year
- KTCC N/A
- AKTX N/A
- Revenue Next Year
- KTCC N/A
- AKTX N/A
- P/E Ratio
- KTCC N/A
- AKTX N/A
- Revenue Growth
- KTCC N/A
- AKTX N/A
- 52 Week Low
- KTCC $2.21
- AKTX $0.85
- 52 Week High
- KTCC $6.14
- AKTX $4.00
- Technical
- Relative Strength Index (RSI)
- KTCC 41.90
- AKTX 36.44
- Support Level
- KTCC $2.76
- AKTX $0.95
- Resistance Level
- KTCC $2.85
- AKTX $1.01
- Average True Range (ATR)
- KTCC 0.09
- AKTX 0.06
- MACD
- KTCC -0.01
- AKTX -0.00
- Stochastic Oscillator
- KTCC 21.21
- AKTX 5.27
About KTCC Key Tronic Corporation
Key Tronic Corp is an electronic manufacturing service provider. The company provides electronic manufacturing services to original equipment manufacturers in the United States and globally. Its primary services include integrated electronic and mechanical engineering, precision plastic molding, sheet metal fabrication, printed circuit board (PCB) and complete product assembly, component selection, sourcing and procurement, logistics, and new product testing and production. The firm derives a majority of its revenue from the United States.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.